01 / STACK OVERVIEW
The GLOW Protocol
GLOW is Apex's skin, collagen, and tissue rejuvenation stack. Built around GHK-Cu's extraordinary ability to activate over 31 collagen and elastin genes, amplified by BPC-157's local repair and angiogenesis, and supported systemically by TB-500's stem cell mobilization. The result: a comprehensive protocol that works at the genetic level, the cellular level, and the vascular level simultaneously. For skin health, wound healing, anti-aging, and connective tissue restoration.
GHK-Cu
50mg vial · 166.7 mcg/unit
GENE ACTIVATION LEAD
Copper tripeptide naturally found in human plasma. Activates 31+ collagen/elastin synthesis genes. Upregulates antioxidant enzymes (SOD, catalase). Promotes wound closure and hair follicle activation. Resets gene expression toward a younger, more regenerative profile. The anchor compound of the GLOW stack.
TB-500
10mg vial · 33.3 mcg/unit
SYSTEMIC AMPLIFIER
Thymosin Beta-4 synthetic fragment. Mobilizes stem cells throughout the body to sites of tissue damage. Reduces systemic inflammation via NF-κB inhibition. Binds actin to drive cellular motility — critical for wound closure and tissue remodeling. Creates the ideal systemic environment for GHK-Cu's local effects.
BPC-157
10mg vial · 33.3 mcg/unit
LOCAL VASCULAR REPAIR
Body Protection Compound. Drives angiogenesis (new blood vessel formation) via VEGFR2 activation — restoring blood supply to skin and tissue. EGF receptor activation accelerates wound healing and skin cell turnover. Synergizes with GHK-Cu: BPC-157 creates blood supply; GHK-Cu activates the collagen genes that use it.
02 / OUTCOMES & MECHANISMS
What GLOW Delivers
✦
SKIN THICKNESS & ELASTICITY
GHK-Cu activates collagen I, III, and IV genes — the structural proteins that give skin its thickness, firmness, and resistance to wrinkling. Clinical studies show 35% increase in collagen production at target concentrations. Combined with BPC-157's EGF activation, skin cell turnover accelerates and damaged cells are replaced faster.
✦
WOUND HEALING & SCAR REDUCTION
BPC-157 drives angiogenesis (new blood supply to wound bed) while TB-500 mobilizes fibroblasts and stem cells to the site. GHK-Cu then provides the collagen blueprint — producing organized, non-fibrotic scar tissue that more closely matches the original skin architecture. Particularly effective for chronic wounds and post-surgical scars.
✦
ANTIOXIDANT DEFENSE & INFLAMMATION CONTROL
GHK-Cu upregulates superoxide dismutase (SOD) and catalase — the primary cellular antioxidant enzymes. TB-500 inhibits NF-κB (systemic inflammatory signal). Together: oxidative damage is reduced, skin cells live longer, and the inflammatory microenvironment that accelerates aging is suppressed.
✦
HAIR FOLLICLE ACTIVATION
GHK-Cu stimulates hair follicle growth from telogen (resting) back to anagen (active growth) phase. Increases follicle size and hair shaft diameter. Studied in both men and women — clinical data shows reversal of miniaturization pattern in androgenic alopecia. BPC-157's scalp angiogenesis supports the follicle with improved blood supply.
✦
GENE EXPRESSION RESET — ANTI-AGING AT THE ROOT
GHK-Cu's most remarkable property: it resets the gene expression profile of aged cells toward a younger state. Studies show GHK-Cu reverses the expression of genes associated with aging, inflammation, and cancer progression while upregulating genes associated with cellular repair. This is not surface treatment — it's reprogramming.
GLOW STACK — WHAT IT ADDRESSES
Fine lines and wrinkles
Skin thickness and elasticity loss
Wound healing and chronic scars
Hair thinning and follicle miniaturization
Connective tissue laxity
Oxidative skin damage
Post-injury scar tissue quality
GLOW vs. KLOW — CHOOSE YOUR STACK
GLOW: skin, collagen, hair, anti-aging focus
KLOW: adds gut/mucosal repair (KPV) for IBD, leaky gut, autoimmune
GLOW is the right choice when inflammation isn't the primary issue
KLOW is GLOW + KPV — for comprehensive systemic inflammation control
Both share the GHK-Cu + TB-500 + BPC-157 core
03 / RECONSTITUTION
Vial Preparation
GHK-Cu — 50mg VIAL
50mg + 3.0 mL BAC water
166.7 mcg per unit
500mcg: 3 units / 0.03 mL
1mg: 6 units / 0.06 mL
2mg: 12 units / 0.12 mL
TB-500 — 10mg VIAL
10mg + 3.0 mL BAC water
33.3 mcg per unit
1mg: 30 units / 0.30 mL
2mg: 60 units / 0.60 mL
BPC-157 — 10mg VIAL
10mg + 3.0 mL BAC water
33.3 mcg per unit
250mcg: 7.5 units / 0.075 mL
500mcg: 15 units / 0.15 mL
750mcg: 22.5 units / 0.225 mL
GHK-Cu Color Note: Reconstituted GHK-Cu solution will appear blue-green due to the copper component. This is normal and expected — the color confirms proper copper chelation. Do not discard.
Storage (all vials): Lyophilized powder stable at room temp 6 months. After reconstitution: refrigerate (2–8°C), use within 28–30 days. Protect from light. Do NOT freeze reconstituted vials.
04 / DOSING PROTOCOL
Dose Ranges
| COMPOUND |
LOW DOSE |
STANDARD DOSE |
HIGH DOSE |
FREQUENCY |
| GHK-Cu |
500mcg/day |
1mg/day |
2mg/day |
Daily SC |
| TB-500 |
1mg/week |
2mg/week |
4mg/week |
1–2 injections/week |
| BPC-157 |
250mcg/day |
500mcg/day |
750mcg/day |
Daily (can split AM/PM) |
Topical GHK-Cu Concurrent Use: Topical GHK-Cu cream (available separately) can be applied to face, scalp, or wound areas concurrent with SC injections. Topical delivers GHK-Cu directly to dermal target tissue; systemic SC injection provides whole-body collagen gene activation. For skin and hair goals, combining both routes produces superior outcomes versus either alone.
Injection Site for BPC-157: For wound healing or skin-specific applications, inject BPC-157 subcutaneously in close proximity to the target area. Local injection concentrates angiogenic signals at the site. For general anti-aging use, periumbilical (abdominal) injection is sufficient.
05 / INJECTION SCHEDULE
Weekly Protocol
COMPOUND
DAILY / WEEKLY SCHEDULE
SITE / NOTES
GHK-Cu
✓ 1mg every PM (daily)
SC any site; topical to face/scalp concurrent
BPC-157
✓ 500mcg every AM (daily)
SC near target tissue or periumbilical
TB-500
✓ 1mg Mon + 1mg Thu
Any SC site, rotate locations
Protocol Logic: BPC-157 AM drives daytime angiogenesis and local repair signaling. GHK-Cu PM leverages overnight gene expression — collagen synthesis peaks during sleep, and GHK-Cu's gene activation aligns with this window. TB-500 twice weekly maintains systemic stem cell mobilization throughout.
No Fasting Required: Unlike GH secretagogues, none of the GLOW compounds require fasting. Injection timing relative to meals is not critical — consistency of timing matters more than fasting state.
06 / BIOMARKER MONITORING
Recommended Lab Panel
COLLAGEN & TISSUE SYNTHESIS
| MARKER | METHOD | OPTIMAL TARGET | NOTES |
|---|
| P1NPprocollagen type I N-terminal propeptide |
Serum baseline + 8 weeks |
OPTIMALIncreasing |
Primary collagen synthesis marker. GHK-Cu should drive measurable P1NP increase. Most direct readout of collagen gene activation. |
| CTX-IC-terminal telopeptide of type I collagen |
Serum baseline + 8 weeks |
OPTIMALStable or decreasing |
Collagen breakdown marker. P1NP rising + CTX stable = net positive collagen balance. The goal. |
| VEGFvascular endothelial growth factor |
Serum — optional |
OPTIMALElevated vs. baseline |
BPC-157 drives VEGF upregulation. Elevated VEGF confirms angiogenesis signaling is active. |
INFLAMMATION — ANTI-AGING MARKERS
| MARKER | CLINICAL RANGE | OPTIMAL TARGET | NOTES |
|---|
| hs-CRPhigh-sensitivity C-reactive protein |
CLINICAL<3.0 mg/L |
OPTIMAL<0.5 mg/L |
TB-500 + BPC-157 reduce systemic inflammation. Lower CRP = slower biological aging and better collagen preservation. |
| 8-OHdG8-hydroxy-2-deoxyguanosine (urine) |
CLINICAL<15 ng/mg Cr |
OPTIMAL<6 ng/mg Cr |
Oxidative DNA damage marker. GHK-Cu's SOD/catalase upregulation should drive this down — confirms antioxidant mechanism. |
VISUAL / PHYSICAL ASSESSMENT
| METHOD | TIMING | NOTES |
|---|
| Standardized Photographyskin texture, tone, wrinkle depth |
Week 0 → Week 8 → Week 12 |
Same lighting, angle, distance. Tracks visible changes in skin texture, tone, and firmness. Most patients report visible changes at 8–10 weeks. |
| Hair Density Counttrichoscopy or photograph |
Baseline + 12 weeks |
For hair loss applications — GHK-Cu follicle activation typically measurable at 12 weeks. Use consistent scalp photography area. |
| Skin Elasticitycutometer or pinch test |
Baseline + 12 weeks |
Objective elasticity measurement. GHK-Cu's elastin gene activation improves snap-back time and resistance to deformation. |
| Wound Healing Rateclinical or photographic |
Ongoing during cycle |
For wound healing applications — track wound area reduction over time. BPC-157 effects visible within 7–14 days of local injection. |
SAFETY PANEL
| MARKER | CLINICAL RANGE | NOTES |
|---|
| Serum Coppercopper — serum |
CLINICAL70–140 µg/dL |
Baseline check. GHK-Cu micro-doses copper — relevant if deficiency exists. Excess copper (>200 µg/dL) warrants dose reduction. |
| CBC + CMPcomplete blood count + metabolic panel |
CLINICALStandard |
Baseline + 8 weeks. All three compounds have excellent safety profiles. BPC-157 hepatoprotective — liver values should remain stable or improve. |
07 / CYCLE PROTOCOL
Administration Schedule
MINIMUM BEFORE RESULTS
8 weeks — GHK-Cu's collagen gene activation requires sustained signaling. Skin turnover cycle is approximately 28 days. Allow 2 full skin cycles (8+ weeks) before evaluating visible outcomes.
PEAK RESULTS WINDOW
12–20 weeks — collagen remodeling continues for weeks after the active gene expression changes begin. Continued improvement often reported for 4–8 weeks post-cycle.
OFF PERIOD
4–8 weeks between full cycles. For skin maintenance: GHK-Cu topical cream can bridge cycles between SC injections. BPC-157 can be maintained at 250mcg/day for chronic wound or skin conditions.
UPGRADE PATH
Add KPV 20mg → Full KLOW Stack. Adds upstream NF-κB / cytokine suppression for those with inflammatory conditions, autoimmune skin conditions (psoriasis, eczema), or gut/GI overlap.
REQUIRES
3 vials + BAC water + Apex V3 Pen. ~9 injections/week (2 daily + 2 TB-500 per week). Manageable protocol with Apex pen system. Optional: GHK-Cu topical cream concurrent.
⚠ Research reference only. GHK-Cu, TB-500, and BPC-157 are not FDA-approved for human therapeutic use. Information sourced from published clinical and preclinical literature. Consult a qualified medical provider before use.